Implementation of buprenorphine in the Veterans Health Administration: Results of the first 3 years

Drug and Alcohol Dependence

Volumn 90, Issue 2-3, 2007, Pages 292-296

  Gordon, Adam J ^a   Trafton, Jodie A ^b   Saxon, Andrew J ^c   Gifford, Allen L ^d   Goodman, Francine ^e   Calabrese, Vincent S ^e   McNicholas, Laura ^a   Liberto, Joseph ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d Center for Health Quality Outcomes and Economic Research   (United States)

^e VACO Pharmacy Benefits Management Strategic Healthcare Group (119D)   (United States)

Author keywords

Buprenorphine; Opioid dependence; Treatment; Veterans administration

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE;

ARTICLE; DATA BASE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; GOVERNMENT; HEALTH CARE; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL;

ADMINISTRATION, SUBLINGUAL; ADULT; BUPRENORPHINE; FEMALE; HUMANS; MALE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS;

EID: 34548134819     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2007.03.010     Document Type: Article

References (17)

1. Addiction Management Systems, 2006. Addiction management systems. Available from: http://www.addictionmanagement.com/Benefits.htm. Accessed on: December 5, 2006.
2. Dalton A., Saweikis M., McKellar J.D., 2006. Health services for VA substance use disorder patients. Comparison of utilization in fiscal years 2005, 2004, 2003, and 2002. Available from: http://www.chce.research.med.va.gov/pdf/2005Yellowbook.pdf. Accessed on: December 6, 2006.
3. Fiellin D.A., and O'Connor P.G. Office-based treatment of opioid dependent patients. N. Engl. J. Med. 347 11 (2002) 339-345
4. Fiellin D.A., Pantalon M.V., Chawarski M.C., Moore B.A., Sullivan L.E., O'Connor P.G., and Schottenfeld R.S. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N. Engl. J. Med. 355 4 (2006) 365-374
5. Fiellin D.A., Rosenheck R.A., and Kosten T.R. Office-based treatment for opioid dependence: reaching new patient populations. Am. J. Psychiatry 158 8 (2001) 1200-1204
6. Fudala P.J., Bridge T.P., Herbert S., Williford W.O., Chiang C.N., Jones K., Collins J., Raisch D., Casadonte P., Goldsmith R.J., Ling W., Malkerneker U., McNicholas L., Renner J., Stine S., and Tusel D. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N. Engl. J. Med. 349 10 (2003) 949-958
7. Goodman F., Gordon A., Kivlahan D., Dalack G., Pope J., McNicholas L., Suchinsky R. for the VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel. Criteria for non-formulary use of Buprenophine Sublingual tablets for Opioid Dependence, Criteria for Use Monograph. 2003.
8. Krantz M.J., and Mehler P.S. Treating opioid dependence. Growing implications for primary care. Arch. Intern. Med. 164 3 (2004) 277-288
9. Mark T.L., Woody G.E., Juday T., and Kleber H.D. The economic costs of heroin addiction in the United States. Drug Alcohol Depend. 61 2 (2001) 195-206
10. Marsch L.A. The efficacy of methadone maintenance interventions in reducing illicit opiate use. HIV risk behavior and criminality: a meta-analysis. Addiction 93 4 (1998) 515-532
11. Mattick R.P., Breen C., Kimber J., and Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev. 2 (2003) CD002209
12. McKellar J.D., and Saweikis M. Health Services For VA Substance Use Disorder Patients: Comparison of Utilization in Fiscal Years 2004, 2003 And 1998 (2005), Program Evaluation and Resource Center and HSR&D Center for Health Care Evaluation, VA Palo Alto Health Care System, Palo Alto, CA
13. O'Connor P.G., and Fiellin D.A. Pharmacologic treatment of heroin-dependent patients. Ann. Intern. Med. 133 1 (2000) 40-54
14. Raisch D.W., Fye C.L., Boardman K.D., and Sather M.R. Opioid dependence treatment, including buprenorphine/naloxone. Ann. Pharmacother. 36 2 (2002) 312-321
15. Stanton A., McLeod C., Luckey B., Kissin W.B., Sonnefeld L.J., 2006. SAMHSA/CSAT evaluation of the buprenorphine waiver program. Expanding treatment of opioid dependence: initial physician and patient experiences with the adoption of buprenorphine. Available from: http://buprenorphine.samhsa.gov/ASAM_06_Final_Results.pdf. Accessed on: December 5, 2006.
16. Stein M.D., Cioe P., and Friedmann P.D. Buprenorphine retention in primary care. J. Gen. Intern. Med. 20 11 (2005) 1038-1041
17. United States Government Accountability Office. Glossary of Terms Used in the Federal Budget Process. Revised, fifth ed. (2005), United States Government Accountability Office